Zonnic Pepparmint Munnholsúði, lausn 1 mg/úða Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zonnic pepparmint munnholsúði, lausn 1 mg/úða

niconovum ab - nicotinum - munnholsúði, lausn - 1 mg/úða

Zonnic Mint Munnholspúði 4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

zonnic mint munnholspúði 4 mg

niconovum ab - nicotinum - munnholspúði - 4 mg

Omnic Hart hylki með breyttan losunarhraða 0,4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

omnic hart hylki með breyttan losunarhraða 0,4 mg

astellas pharma a/s* - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg

Alpha Ject 3000 Stungulyf, fleyti Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject 3000 stungulyf, fleyti

pharmaq as* - aeromonas salmonicida subs. salmonicida al 2017; vibrio anguillarum serotype o1 al 112; vibrio anguillarum serotype 02 al 104 - stungulyf, fleyti

ALPHA JECT 5-3 Stungulyf, fleyti Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject 5-3 stungulyf, fleyti

pharmaq as* - aeromonas salmonicida subsp. salmonicida; vibrio salmonicida; listonella anguillarum serotype o1; listonella anguillarum serotype o2a; moritella viscosa - stungulyf, fleyti

Alpha Ject micro 5 Stungulyf, fleyti ein. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject micro 5 stungulyf, fleyti ein.

pharmaq as* - aeromonas salmonicida subs. salmonicida al 2017; vibrio anguillarum serotype o1 al 112; vibrio anguillarum serotype 02 al 104; moritella viscosa; vibrio salmonicida - stungulyf, fleyti - ein.

Namuscla Evrópusambandið - íslenska - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic kvilla - hjarta meðferð - namuscla er ætlað fyrir einkennum meðferð vöðvaherping í fullorðinn sjúklinga með ekki-dystrophic myotonic kvilla.

Pro-Epanutin Stungulyf, lausn/innrennslisþykkni, lausn 50 mg FE/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pro-epanutin stungulyf, lausn/innrennslisþykkni, lausn 50 mg fe/ml

pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml

Lacosamide Adroiq Evrópusambandið - íslenska - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lacosamíð - flogaveiki - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Lacosamide Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lacosamíð - flogaveiki - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.